Oral Session 1-7D Multiple Myeloma: Novel Agents

[OS1-7D-3] Efficacy of elotuzumab/lenalidomide/dexamethasone in myeloma patients in real-world practice

Saori Soeda¹, Takuya Yamashita¹, Atsushi Isoda², Kazuhito Suzuki³, Toru Kiguchi⁴, Norina Tanaka⁵, Junji Tanaka⁵, Makoto Sasaki⁶, Norio Komatsu⁶, Hiroshi Yasui⁷, Yoichi Imai⁷, Jian Hua⁸, Masao Hagihara⁸, Mariko Ishibashi⁹, Koichi Inokuchi¹⁰, Yasunobu Sekiguchi¹¹, Masaaki Noguchi¹¹, Hideto Tamura¹⁰ (1.Hematology Department, Luke's International University, 2.Department of Hematology, National Hospital Organization Shibukawa Medical Center, 3.Division of Clinical Oncology/Hematology, the Jikei University Kashiwa Hospital, 4.Department of Hematology, Chugoku Central Hospital, 5.Department of Hematology, Tokyo Women's Medical University, 6.Division of Hematology, Juntendo University School of Medicine, 7.Dep Hematology/Oncology, The Institute of Medical Science, University of Tokyo, 8.Department of Hematology, Eiju General Hospital, 9.Department of Microbiology and Immunology, Nippon Medical School, 10.Department of Hematology, Nippon Medical School, 11.Department of Hematology, Juntendo University Urayasu Hospital)